Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B), while Vanguard Total Stock Market Index Fund ETF trades at $381.48 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 17.9× Vertex Pharmaceuticals Incorporated's market cap, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Vanguard Total Stock Market Index Fund ETF for 131 Days on average.
| VRTX | VTI | |
|---|---|---|
Market Cap | $128.16B | $2.30T |
Volume | 806,603 | 2,730,571 |
Sector | Health | — |
52-Week High | $557.96 | $384.30 |
52-Week Low | $407.37 | $311.68 |
Typical Hold Time | 120 Days | 131 Days |
Enterprise Value | $122.29B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
VTI trades at $381.03, down 0.39% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF maintains strong diversification across the U.S. equity market, though key financial ratios are not provided in the snapshot. Recent news highlights long-term growth potential and comparisons with similar funds like VOO.
The outlook for VTI remains positive given broad market exposure and low-cost structure, but risks include concentration in top holdings and market volatility. Analyst sentiment is generally favorable for long-term investors, emphasizing diversification benefits and historical performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
